Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4098 | Tuberculin test Wiki | 0.71 |
| drug1176 | Deferoxamine Wiki | 0.50 |
Navigate: Correlations HPO
There are 2 clinical trials
Both mindfulness meditation and expectancy effects are known to reduce pain intensity, pain unpleasantness and pain catastrophizing, but it is unknown whether and how expectancy effects contribute to the overall effect of mindfulness meditation on these outcomes, especially during significant global events such as the coronavirus pandemic. This study includes four interrelated aims that will probe these effects and interactions.
Description: Assessed via a numerical rating scale (0=no pain, 10=most intense pain imaginable)
Measure: Pain intensity Time: 40 minutesDescription: assessed via a numerical rating scale (0=no pain, 10=most unpleasant pain imaginable)
Measure: Pain Unpleasantness Time: 40 minutesDescription: assessed via the Pain Catastrophizing Scale (PCS; 0=no catastrophizing, 52=highest catastrophizing, 30+=clinically significant catastrophizing)
Measure: Pain Catastrophizing Time: 40 minutesDescription: assessed via self-report questions (0=lowest expectancy, 10=highest expectancy)
Measure: Expectancy Time: 40 minutesDescription: assessed via the Pain-related Cognitive Processes Questionnaire (PCPQ-R; 0=lowest reappraisal, 4=highest reappraisal)
Measure: Pain Reappraisal Time: 40 minutesDescription: assessed via the Five Facet Mindfulness Questionnaire Observing Subscale (FFMQ-O; 1=lowest observing, 5=highest observing)
Measure: Mindful observing Time: 40 minutesDescription: assessed via the Five Facet Mindfulness Questionnaire Non-reacting Subscale (FFMQ-NR; 1=lowest non-reactivity, 5=highest non-reactivity)
Measure: Mindful non-reactivity Time: 40 minutesDescription: assessed via the State Mindfulness Survey (SMS; 1=lowest mindfulness, 21=highest mindfulness)
Measure: State Mindfulness Time: 40 minutesDescription: assessed via the Metacognitive Processes of Decentering - State (MpoD-s; 0=lowest decentering, 3=highest decentering)
Measure: State Decentering Time: 40 minutesBoth mindfulness meditation and expectancy effects are known to reduce anxiety, stress and catastrophizing, but it is unknown whether and how expectancy effects contribute to the overall effect of mindfulness meditation on these outcomes, especially during significant global events such as the coronavirus pandemic. This study includes four interrelated aims that will probe these effects and interactions.
Description: assessed via a covid-19-related catastrophizing scale (CCS; 0=no catastrophizing, 52=highest catastrophizing, 30+=clinically significant catastrophizing)
Measure: Coronavirus-related catastrophizing Time: 40 minutesDescription: assessed via self-report questions (0=lowest expectancy, 10=highest expectancy)
Measure: Expectancy Time: 40 minutesDescription: assessed via the Cognitive Emotion Regulation Questionnaire (CERQ-R; 4=lowest reappraisal, 20=highest reappraisal)
Measure: Reappraisal Time: 40 minutesDescription: assessed via the Five Facet Mindfulness Questionnaire Observing subscale (FFMQ-O; 1=lowest observing, 5=highest observing)
Measure: Mindful observing Time: 40 minutesDescription: assessed via the Five Facet Mindfulness Questionnaire Non-reacting subscale (FFMQ-NR; 1=lowest non-reactivity, 5=highest non-reactivity)
Measure: Mindful non-reactivity Time: 40 minutesDescription: assessed via the State Mindfulness Survey (SMS; 1=lowest mindfulness, 21=highest mindfulness)
Measure: State Mindfulness Time: 40 minutesDescription: assessed via the Metacognitive Processes of Decentering - State (MpoD-s; 0=lowest decentering, 3=highest decentering)
Measure: State Decentering Time: 40 minutesAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports